Glenmark Pharmaceuticals reduces price of breast cancer drug Trastuzumab

15 Jun 2023 Evaluate

Glenmark Pharmaceuticals has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier. Trastuzumab is used in the treatment of a particular type of breast cancer HER2-positive and the company markets its version in India under the brand name 'Trumab'.

This price reduction will bring the per mg cost of Trumab to around Rs 35, making it the most affordable treatment option for HER2-positive breast cancer in the country.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2065.95 40.55 (2.00%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×